PALD Inhibitors
PALD inhibitors belong to a chemical class of compounds designed to interact with and modulate the activity of a specific enzyme known as Pyridoxalase (PALD). This enzyme is involved in the metabolism of pyridoxal, which is the aldehyde form of vitamin B6. Pyridoxalase typically catalyzes the detoxification of pyridoxal, converting it into a less reactive form. The inhibitors of this enzyme are structurally diverse, but they share the common feature of being able to bind to the active site of pyridoxalase, thereby hindering its normal enzymatic function. This inhibition can lead to an increase in the concentration of pyridoxal within the system.
The design of PALD inhibitors is a complex process that takes into account the enzyme's binding sites and the chemical properties of both the enzyme and the potential inhibitors. The inhibitors often mimic the structure of the enzyme's natural substrates or products, thereby allowing them to fit snugly into the enzyme's active site. This molecular mimicry is a common strategy in the development of enzyme inhibitors. The binding of these inhibitors can be reversible or irreversible, depending on the nature of the interaction between the inhibitor and the enzyme. Some inhibitors form covalent bonds with the enzyme, leading to permanent inactivation, while others form non-covalent interactions that allow for the inhibitor to dissociate and leave the enzyme intact. The structural conformation of PALD after inhibitor binding is crucial, as it can induce changes in the enzyme's configuration, further impacting its functionality.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitoleic acid | 373-49-9 | sc-205424 sc-205424A sc-205424B sc-205424C sc-205424D | 100 mg 500 mg 1 g 5 g 10 g | $32.00 $132.00 $233.00 $1019.00 $1870.00 | 4 | |
As a monounsaturated fatty acid, palmitoleic acid can integrate into cell membranes and modulate the activity of membrane-bound proteins. For PALD, which may be involved in lipid metabolism or membrane dynamics, the presence of palmitoleic acid could alter the lipid composition of membranes, thereby indirectly inhibiting PALD's function by changing its local environment and potentially its activity. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), which is involved in the production of ceramide from sphingomyelin. If PALD's function is related to ceramide signaling or metabolism, the inhibition of nSMase by GW4869 could lead to decreased activation or functionality of PALD. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. If PALD is involved in this pathway or is regulated by it, PD98059 could indirectly inhibit PALD by preventing the activation of ERK, which may be necessary for PALD's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a key role in the AKT signaling pathway. If PALD is downstream of PI3K/AKT signaling or is modulated by it, LY294002 could indirectly inhibit PALD by blocking PI3K and thereby reducing AKT activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key regulator of cell growth and protein synthesis. If PALD is involved in pathways regulated by mTOR, rapamycin could indirectly inhibit PALD by dampening mTOR signaling and its downstream effects. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is implicated in inflammatory responses and stress-activated pathways. If PALD's activity is modulated by p38 MAPK, inhibition by SB203580 could lead to decreased PALD activity by suppressing the signaling through this kinase. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. If PALD is affected by PI3K-mediated signals, the inhibition of PI3K by wortmannin would lead to a reduction in PALD activation due to the downstream effects on AKT signaling. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
Z-VAD-FMK is a broad-spectrum caspase inhibitor. If PALD is involved in apoptotic pathways regulated by caspases, the inhibition of these proteases could indirectly inhibit PALD by preventing the execution of apoptosis, which might affect PALD's function. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is an inhibitor of protein kinase C (PKC). If PALD is regulated by PKC-mediated phosphorylation or is part of signaling pathways involving PKC, chelerythrine could decrease PALD's activity by inhibiting PKC's activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If PALD is part of the JNK signaling pathway or is influenced by it, inhibition of JNK by SP600125 could lead to decreased activity of PALD due to disruption of JNK-mediated signaling. | ||||||